Aspen Neuroscience, Inc. (NASDAQ:ASPE - Get Free Report) Director Peter Thompson acquired 1,000,000 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $15,000,000.00. Following the completion of the acquisition, the director directly owned 3,589,132 shares in the company, valued at approximately $53,836,980. This represents a 38.62% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Aspen Neuroscience Stock Performance
NASDAQ:ASPE opened at $12.76 on Thursday. Aspen Neuroscience, Inc. has a 1 year low of $11.20 and a 1 year high of $14.90.
Aspen Neuroscience Company Profile
(
Get Free Report)
Aspen Neuroscience, Inc is a biotechnology company focused on developing regenerative medicine therapies for neurological disorders. The company's approach uses a patient's own cells to create induced pluripotent stem cells, which are then differentiated into specialized cells intended to replace damaged or lost tissue.
Aspen's lead program, ANPD001, is designed as a potential cell replacement therapy for Parkinson's disease. The company has also developed genetic screening and manufacturing processes intended to evaluate a patient's cells and produce an individualized therapeutic product.
Aspen Neuroscience is headquartered in San Diego, California.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
